• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • Instagram
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • What is ALS/MND
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights of People with ALS/MND and Caregivers
    • Research
      • Open Science
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
      • Open Label Extension
    • Advocacy
      • Advocacy Toolkit
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
    • Drugs in Development
      • AB Science – Masitinib
      • Amylyx – AMX0035
      • Biogen – Tofersen
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Orphazyme – Arimoclomol
      • T Regulatory Cell Therapies
    • Approved Drugs
      • Radicava/Edaravone
      • Neudexta
      • Riluzole/Tiglutik
  • Support for Health Professionals
    • How to Break the News in ALS/MND
  • Events/Programs
    • Calendar of Events/Programs
    • Alliance Webinars
    • Alliance Meeting
    • Allied Professionals Forum
    • ALS/MND Connect
    • Global Day
    • March of Faces
    • International Symposium on ALS/MND
  • About
    • Who We Are
    • Board of Directors
    • Committees/Advisory Councils
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Innovation and Technology Council
      • Governance Committee
      • Budget and Finance Committee
    • Staff
    • History
    • Archives
      • Newsletters
      • Meetings
    • Awards
      • Student Award Nomination
      • Forbes Norris Award Nomination
      • Humanitarian Award Nomination
      • Allied Health Professional Award Nomination
  • Members
    • Member Registration
    • Forgot Password

BrainStorm Cell Therapeutics – NurOwn

BrainStorm Cell Therapeutics – NurOwn

Background

The BrainStorm treatment regimen consists of a person’s own stem cells (called autologous) being removed from bone marrow and then grown outside of the body in the presence of a chemical owned by the company, called NurOwn, which aims to increase the stem cells’ ability to make and secrete protective substances called growth factors. The stem cells are then injected into the fluid that bathes the brain and spinal cord (called cerebrospinal fluid or CSF) with a needle (called intrathecal or IT injection) at multiple intervals. The hope is that these treated stem cells will be able to slow the progression of motor neuron degeneration and hence, the progression of ALS symptoms.

In 2016, the first peer reviewed publication appeared, demonstrating preliminary, positive safety data in combination with BrainStorm completing a phase 2 clinical trial at three renowned US clinical sites.

The phase 2 trial data involved 48 ALS patients (36 treated and 12 placebo) and was published in December 2019 in the journal Neurology, titled “A single-dose transplantation of MSC-NTF cells is safe and demonstrated early promising signs of efficacy.”

A phase 3 clinical trial testing multiple doses of NurOwn at six sites in the United States was started in 2017. The trial was double-blinded, meaning neither researchers nor participants knew if they were on active treatment or placebo. The primary measurements were to examine safety of repeated intrathecal injections of NurOwn and the ability of NurOwn to slow progression of ALS/MND using a scale called the ALSFRS-R. To determine if NurOwn-treated stem cells were providing the intended biological effect, the CSF was measured for biomarkers including neurotrophic factors (aiming for increased levels) and neurodegenerative/neuroinflammatory factors (aiming for reduced levels).

On November 17, 2020, a press release was issued describing the initial data from the phase 3 clinical trial. The trial did not meet statistical significance in any of the reported data, notably in the primary measurement of disease progression using the ALSFRS-R. A pre-specified subgroup of those with early disease was highlighted in the press release as showing clinically meaningful slowing of ALS progression, however these results were also not statistically significant. Further, it was reported that that NurOwn treatment resulted in an increase of neurotrophic biomarkers and reduction in neurodegenerative and neuroinflammatory biomarkers when compared to the placebo group, which is aligned with what the trial hoped to achieve. Follow up analysis will investigate whether these biomarker results, in addition to further analysis of the pre-specified subgroup of those with early disease, can reveal any additional information. As of January 2021, this recommendation is based also on additional data presented at the International ALS/MND Symposium on December 9, 2020.

On December 10, 2021, the NurOwn phase 3 data was published in the journal Muscle & Nerve, titled “A Randomized Placebo-Controlled Phase 3 Study of Mesenchymal stem cells induced to secrete high levels of neurotrophic factors in Amyotrophic Lateral Sclerosis.”As summarized at the beginning of the discussion “The primary and secondary efficacy endpoints of this Phase 3, placebo-controlled, randomized trial were not statistically significant, however the study provided significant information about the study design and potential biomarkers of treatment response for use in future clinical trials.”

In brief, none of the pre-specificed analyses demonstrated a significant benefit of NurOwn over placebo. The most commonly discussed comparison from this data amongst the ALS community, regarding a measurement of responders in a pre-specificed subgroup of indiviuals >35 ALSFRS-R score at baseline, demonstrated that 9 of 26 individuals met responder criteria on NurOwn, while 5 of 32 individuals responded to placebo. While this trends towards benefit of NurOwn, the comparison is not statistically significant (p=0.29) and a difference of only four individuals, indicating that there is no way to know if the response of the NurOwn group is due to treatment, or the same effects as experienced by the five individuals in the placebo group. Of note, this pre-specified subgroup does not appear to be specified in the study protocol published online here.

Post hoc analyses reveal trends to indicate NurOwn could have some level of efficacy that could suggest a follow-up clinical trial, using the learnings from this study, may be of value. These types of post hoc analyses, particularly where “no adjustments were made for multiple comparisons in testing exploratory efficacy endpoints”, are generally not used as evidence of benefit, but to inform further study. This is a practice accepted widely in industry for good clinical development, as conclusions drawn from post hoc analyses can be misleading.

NurOwn did demonstrate the anticipated significant increase in neurotrophic factors, such as VEGF and decrease in neuroinflammatory markers like MCP-1, but did not significantly alter NfL levels. These biomarker results tell us that NurOwn achieved the desired biological effect, to some extent. None of these biomarkers are as yet validated or accepted as indicative of clinical effect and the marker closest to a wider acceptance as indication of neuronal health, NfL, was not significantly decreased by NurOwn over placebo. A trend towards decrease in NfL provides some supporting evidence for the value of another trial.

Finally, a number of individuals who participated in the phase 3 clinical trial have publicly shared their positive experiences. In the absence of convincing point data indicating a clear number of individuals treated with NurOwn, rather than placebo, who had a radical change in trajectory of disease progression, it is impossible for anyone to know if this can be attributed to an effect of NurOwn. Furthermore, a published secondary endpoint of individuals demonstrating >100% improvement in ALSFRS-R slope, revealed 13 individuals in both the NurOwn- and placebo-treated groups, including 7 of the 9 individuals on NurOwn in the >35 baseline ALSFRS-R group and 5 of the 5 individuals on placebo.

It is also not possible to determine the contribution of NurOwn to any experiences in Expanded Access or Hospital Exemption programs, though once collected, data from these may be valuable in helping BrainStorm to determine a path forward for any future trial.

Recommendation

The SAC recommends that there is insufficient evidence at this time to conclude that NurOwn provides any benefit to people with ALS. Given that extensive post hoc analysis revealed possible trends suggesting that NurOwn may provide some level of clinical benefit over placebo, any path forward should involve a second phase 3 clinical trial using the learnings to date. Regarding the multiple anecdotal reports of benefit, no point data has been released to demonstrate a significant number of individual experiences have greatly benefited from NurOwn over placebo.

International Alliance of ALS/MND Associations
January 2022


The original language of communication is English and any translation cannot be guaranteed for accuracy of messaging.

Primary Sidebar

Drugs in Clinical Trial

  • AB Science – Masitinib
  • Amylyx – AMX0035
  • Biogen – Tofersen
  • BrainStorm Cell Therapeutics – NurOwn
  • Clene Nanomedicine – CNM-Au8
  • Collaborative Medicinal Development – CuATSM
  • Cytokinetics – Reldesemtiv
  • Kadimastem – AstroRx
  • Mitsubishi Tanabe Pharma America – Oral Edaravone
  • Orphazyme – Arimoclomol
  • T Regulatory Cell Therapies

  • England-Lee-Millard, UK

    England-Lee-Millard, UK

  • Inta Grubb, Diagnosed 2014 - MND Australia

    Inta Grubb, Diagnosed 2014 – MND Australia

  • Alberto Baez Murillo, Colombia

    Alberto Baez Murillo, Colombia

  • Eddy LeFrançois, Diagnosed 1992 - ALS Canada

    Eddy LeFrançois, Diagnosed 1992 – ALS Canada

  • Claire Garry, USA

    Claire Garry, USA
    20200117_214643

  • Peng Yi-Wen

    Peng Yi-Wen

  • Steven Gallagher, Canada

    Steven Gallagher, Canada

  • Cath Muir

    Cath Muir
    Cath

  • Fabrice Kamp, Germany

    Fabrice Kamp, Germany

  • Dorette Lüdi, Diagnosed 2014 - ALS Schweiz, Switzerland

    Dorette Lüdi, Diagnosed 2014 – ALS Schweiz, Switzerland

  • Wilfried Leusing, Diagnosed 2010 - DGM, Germany

    Wilfried Leusing, Diagnosed 2010 – DGM, Germany

  • Roy

    Roy
    roy

  • Charlie “Hark” Dourney, Diagnosed 2007 - Hark ALS, USA

    Charlie “Hark” Dourney, Diagnosed 2007 – Hark ALS, USA

  • Fabio Correia

    Fabio Correia

  • Guido De Mets, Belgium

    Guido De Mets, Belgium

  • Duncan Bayly - MND Australia

    Duncan Bayly – MND Australia

  • Maurice LeClerc, ALS Canada

    Maurice LeClerc, ALS Canada

  • Jeff Sutherland

    Jeff Sutherland
    jspic

  • Jon Newsome, Les Turner ALS Foundation, USA

    Jon Newsome, Les Turner ALS Foundation, USA

  • Valdomiro Xavier Honório, Brazil

    Valdomiro Xavier Honório, Brazil

  • Nicholas (Nic) Bowman, MND Association of South Africa, Diagnosed 2016, Australia

    Nicholas (Nic) Bowman, MND Association of South Africa, Diagnosed 2016, Australia

  • UK-Mahmood-Anwar

    UK-Mahmood-Anwar

  • Chun Ju Xiao, China

    Chun Ju Xiao, China

  • Oliver Juenke, DGM, Germany

    Oliver Juenke, DGM, Germany

  • Luis Antonio Pimenta Lima, Brazil

    Luis Antonio Pimenta Lima, Brazil

  • David Watson, MND Scotland, Diagnosed 2018, Scotland

    David Watson, MND Scotland, Diagnosed 2018, Scotland

  • John and Loretta Russo, USA

    John and Loretta Russo, USA
    final3878

  • Fernando Ocampo Cardona, Colombia

    Fernando Ocampo Cardona, Colombia

  • Joyce Rusinak, Forbes Norris ALS Center, USA

    Joyce Rusinak, Forbes Norris ALS Center, USA

  • Brian Lovell, Diagnosed 2011 - MND Australia

    Brian Lovell, Diagnosed 2011 – MND Australia

  • Christian Bär, Germany

    Christian Bär, Germany

  • Ali Var, Turkey

    Ali Var, Turkey

  • Susan Anderson, Diagnosed 2014 - Hope Loves Company, USA

    Susan Anderson, Diagnosed 2014 – Hope Loves Company, USA

  • Josée Kolijn-de Man, Diagnosed 2015 - ALS Patients Connected, The Netherlands

    Josée Kolijn-de Man, Diagnosed 2015 – ALS Patients Connected, The Netherlands

  • Irene McCaughey, Diagnosed 2011 - MND Australia

    Irene McCaughey, Diagnosed 2011 – MND Australia

  • Brigitte Wernli, Association ALS Switzerland, Diagnosed 2014, Switzerland

    Brigitte Wernli, Association ALS Switzerland, Diagnosed 2014, Switzerland

  • Ailsa Malcolm-Hutton, Diagnosed 2013 - MND Association of England, Wales and N Ireland

    Ailsa Malcolm-Hutton, Diagnosed 2013 – MND Association of England, Wales and N Ireland

  • Conny van der Meijden, Diagnosed 2001 - ALS Netherlands

    Conny van der Meijden, Diagnosed 2001 – ALS Netherlands

  • Rolf Mauch, Association ALS Switzerland, Diagnosed 2015, Switzerland

    Rolf Mauch, Association ALS Switzerland, Diagnosed 2015, Switzerland

  • Kirsten Harley, Diagnosed 2013 - Australia

    Kirsten Harley, Diagnosed 2013 – Australia

  • Osiel Mendoza, Diagnosed 2016 - ALS Therapy Development Institute, USA

    Osiel Mendoza, Diagnosed 2016 – ALS Therapy Development Institute, USA

  • Francisco Perez Palop, Diagnosed 2013 - FUNDELA, Spain

    Francisco Perez Palop, Diagnosed 2013 – FUNDELA, Spain

  • Catherine Pearce, Australia

    Catherine Pearce, Australia

  • Daniel Hare

    Daniel Hare

  • Amparo Muriel Engativa, Colombia

    Amparo Muriel Engativa, Colombia

  • Elisabeth Zahnd, Switzerland

    Elisabeth Zahnd, Switzerland

  • Soledad Rodriguez, FUNDELA, Diagnosed 2013, Spain

    Soledad Rodriguez, FUNDELA, Diagnosed 2013, Spain

  • Angie Bordaen, Diagnosed 2014 - ALS Liga België, Belgium

    Angie Bordaen, Diagnosed 2014 – ALS Liga België, Belgium

  • Orlando Ruiz, Diagnosed 2001 - ACELA, Colombia

    Orlando Ruiz, Diagnosed 2001 – ACELA, Colombia

  • Antonio Ventriglia, ALS Liga Belgium, Diagnosed 2013, Belgium

    Antonio Ventriglia, ALS Liga Belgium, Diagnosed 2013, Belgium

Learn more about the March of Faces

Latest Tweets

  • Just now

Subscribe to our Bi-Monthly Newsletter

Fill out the form below to subscribe to the Alliance’s bi-monthly newsletter, packed with updates from members associations from around the world!

Footer

Keep in touch

Sign up to receive updates and to hear what's going on in the International Alliance of ALS/MND Associations.

"*" indicates required fields

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • Instagram
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2023 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login